<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Draft Guidance for Industry on Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint To Support Accelerated Approval; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Draft Guidance for Industry on Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint To Support Accelerated Approval; Availability</h1>
    <p class="timestamp">Published: 2012-05-30 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval." FDA's accelerated approval regulations permit approval of a new drug to treat a serious disease on the basis of an effect on a surrogate endpoint reasonably likely to predict the clinical benefit of the drug. This draft guidance is intended...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2012-12928</p>
    <p><strong>Publication Date:</strong> 2012-05-30</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2012/05/30/2012-12928/draft-guidance-for-industry-on-pathologic-complete-response-in-neoadjuvant-treatment-of-high-risk">https://www.federalregister.gov/documents/2012/05/30/2012-12928/draft-guidance-for-industry-on-pathologic-complete-response-in-neoadjuvant-treatment-of-high-risk</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2012-12928</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
